Q1 2026 · 13F-HR
venBio Partners LLCholdings as filed
Filed 2026-05-15 · accession 0000905148-26-002409
$280.6M
Reported value
6
Positions
2026-03-31
Period end
The Brief · venBio Partners LLC · Q1 2026
AI · grounded in 13F
venBio Partners LLC increased its position in ALXO by 32.83%. The fund trimmed its holdings in ARTV by 18.07% and reduced its stake in ALMS by 1.98%. The fund ended the period with 6 positions and total assets under management of $280.55M.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| N69605108 | PHVS | PHARVARIS N V | $131.1M | 46.7% | 4,639,304 | Common | SOLE |
| 022307102 | ALMS | ALUMIS INC | $99.8M | 35.6% | 4,528,408 | Common | SOLE |
| 00166B105 | ALXO | ALX ONCOLOGY HLDGS INC | $25.8M | 9.21% | 12,884,638 | Common | SOLE |
| 413197104 | HRMY | HARMONY BIOSCIENCES HLDGS IN | $13.7M | 4.88% | 489,194 | Common | SOLE |
| 55083R203 | LYEL | LYELL IMMUNOPHARMA INC | $6.8M | 2.41% | 337,697 | Common | SOLE |
| 04317A107 | ARTV | ARTIVA BIOTHERAPEUTICS INC | $3.4M | 1.22% | 531,337 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.